Loading clinical trials...
Loading clinical trials...
A Phase 1B Open Label Evaluation of the PK and PD of Dotinurad and Drug-Drug Interaction of Dotinurad and Allopurinol in U.S. Patients with Gout and Hyperuricemia
Conditions
Interventions
dontinurad
dotinurad + allopurinol
+1 more
Locations
4
United States
Clinical Research of West Florida
Clearwater, Florida, United States
Panax Clinical Research
Miami Lakes, Florida, United States
Southwest Rheumatology Research
Mesquite, Texas, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
Start Date
October 4, 2023
Primary Completion Date
June 27, 2024
Completion Date
July 9, 2024
Last Updated
January 28, 2025
NCT07089888
NCT07453004
NCT07504146
NCT07089875
NCT07116746
NCT06310967
Lead Sponsor
Urica Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions